Immatics NV
NASDAQ:IMTX
Immatics NV
Intangible Assets
Immatics NV
Intangible Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Intangible Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Immatics NV
NASDAQ:IMTX
|
Intangible Assets
€1.6m
|
CAGR 3-Years
8%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
BioNTech SE
NASDAQ:BNTX
|
Intangible Assets
€790.4m
|
CAGR 3-Years
76%
|
CAGR 5-Years
56%
|
CAGR 10-Years
N/A
|
|
|
MorphoSys AG
XETRA:MOR
|
Intangible Assets
€786.3m
|
CAGR 3-Years
125%
|
CAGR 5-Years
79%
|
CAGR 10-Years
40%
|
|
|
CureVac NV
NASDAQ:CVAC
|
Intangible Assets
€15.9m
|
CAGR 3-Years
4%
|
CAGR 5-Years
21%
|
CAGR 10-Years
N/A
|
|
|
Biotest AG
XETRA:BIO
|
Intangible Assets
€16.4m
|
CAGR 3-Years
7%
|
CAGR 5-Years
3%
|
CAGR 10-Years
-10%
|
|
|
Formycon AG
XETRA:FYB
|
Intangible Assets
€444.1m
|
CAGR 3-Years
749%
|
CAGR 5-Years
368%
|
CAGR 10-Years
N/A
|
|
Immatics NV
Glance View
Immatics NV is a clinical stage biopharmaceutical company, which engages in the research and development of T cell receptor-based immunotherapies for the treatment of cancer. The company is headquartered in Tuebingen, Baden-Wuerttemberg and currently employs 188 full-time employees. The firm is focused on the discovery and development of T-Cell eceptors with the goal of enabling a robust and specific T-Cell response against these targets. The firm develops targeted immunotherapies with an emphasis on treating solid tumors through two distinct therapeutic modalities: Adoptive Cell Therapies (ACT) and antibody-like TCR Bispecifics (TCER). Its wholly owned pipeline comprises of eight therapeutic programs, of which four are in clinical trials, including IMA201 (MAGEA4/8), IMA202 (MAGEA1) and ACTolog IMA 101 (Multi-target pilot trial) for solid cancers and IMA203 (PRAME) for hematological and solid cancers, as well as four are in preclinical development, including IMA204 (COL6A3) and IMA401 (Cancer testis antigen) for solid cancers, and ACTallo IMA301 (Cancer testis antigen) and IMA402 (Cancer testis antigen) for hematological and solid cancers.
See Also
What is Immatics NV's Intangible Assets?
Intangible Assets
1.6m
EUR
Based on the financial report for Dec 31, 2024, Immatics NV's Intangible Assets amounts to 1.6m EUR.
What is Immatics NV's Intangible Assets growth rate?
Intangible Assets CAGR 3Y
8%
Over the last year, the Intangible Assets growth was 7%. The average annual Intangible Assets growth rates for Immatics NV have been 8% over the past three years .
You don't have any saved screeners yet